US FDA Says Data Integrity Remains Challenging For API Manufacturers

Makers of active pharmaceutical ingredients need to work on improving the integrity of their manufacturing data, if recent US Food and Drug Administration warning letters are any indication.

In recent years, FDA warning letters were more likely to cite data integrity issues if they went to API manufacturers than if they went to drug product manufacturers, according to...